Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy has fundamentally transformed the therapeutic landscape for patients suffering from aggressive, relapsed or refractory hematologic malignancies. By genetically re-engineering a patient's own autologous T cells to express a synthetic receptor targeting the CD19 antigen, CAR-T delivers deep, durable, and frequently curative remissions where conventional multi-agent chemo-immunotherapy and autologous stem cell transplants have failed. Manufactured at its localized state-of-the-art facility in Zhangjiang, Shanghai, Fosun Kite Biotechnology (复星凯特) brought China’s first commercialized autologous CD19-directed CAR-T cell therapy—Axicabtagene Ciloleucel (阿基仑赛注射液 / Ejilunsai / 奕凯达®)—into routine clinical practice.
Because autologous cell therapies involve living human biological material that cannot be exported as an off-the-shelf physical product, international access requires specialized clinical pathway navigation. For international hematology departments, oncology referral networks, and cross-border cancer patients seeking world-class cell therapy at globally competitive costs, China Medical Concierge – Shanghai (CMCS) acts as your authoritative on-ground healthcare navigation liaison and clinical coordination partner in Shanghai.
1. Clinical Indications & Landmark Therapeutic Efficacy
Axicabtagene Ciloleucel is an individualized autologous living cell therapy engineered via retroviral vector transduction to express a chimeric antigen receptor combining a murine anti-CD19 single-chain variable fragment (scFv) with CD28 costimulatory and CD3-zeta signaling domains:
Core Approved Clinical Indications
- Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL): For adult patients who have failed two or more lines of systemic therapy, including Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, and DLBCL transformed from follicular lymphoma.
- Second-Line Indication: Approved for adult patients with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months, serving as an earlier definitive curative option prior to stem cell transplantation.
Real-World Clinical Response & Survival Milestones
- Pivotal and real-world post-marketing multicenter data consistently demonstrate Overall Response Rates (ORR) exceeding 80%, with Complete Response (CR) rates of 50%–60%. Long-term follow-up confirms that patients who attain complete remission frequently experience durable, plateauing progression-free survival, effectively achieving long-term functional cure.
2. Premier Shanghai Academic Medical Centers Utilizing CAR-T
Administering cellular immunotherapy requires specialized clinical infrastructure, including cleanroom apheresis facilities, stem cell transplantation units, and experienced intensive care teams certified in managing Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS):
-
Shanghai Ruijin Hospital (Shanghai Jiao Tong University School of Medicine)
Department of Hematology & State Key Laboratory of Medical Genomics: Globally acclaimed as a preeminent hematology center. Ruijin’s hematology faculty served as principal clinical investigators for commercial CAR-T registration trials in China. The hospital houses specialized bone marrow transplantation wards, dedicated apheresis units, and multidisciplinary toxicity management protocols, having successfully infused and managed hundreds of CAR-T recipients. -
Shanghai Renji Hospital (Shanghai Jiao Tong University School of Medicine)
Division of Hematology: Renowned for translational cellular immunology, personalized conditioning chemotherapy regimens, and comprehensive long-term B-cell aplasia monitoring. -
Shanghai First People's Hospital (Shanghai Jiao Tong University)
Department of Hematology: A high-volume academic center performing complex cellular therapies for hematologic malignancies with standardized ICU backup.
3. Key Structural Differences: Inbound Clinical Access vs. Physical Product Export
International healthcare executives, hospital boards, and referring physicians must understand the critical regulatory distinctions governing autologous cell therapies:
- Autologous Living Cells Cannot Be Exported: Unlike standard pharmaceuticals or medical hardware, CAR-T is not a batch-manufactured drug. It requires collecting the individual patient's own white blood cells via leukapheresis, transporting them in temperature-controlled cryo-containment to the Zhangjiang facility, custom manufacturing the individualized batch (~2–3 weeks), and infusing them back into the same specific patient following lymphodepleting chemotherapy.
- Strict Cross-Border Biosecurity Laws: Under Chinese and international biological border regulations (Class A/B Special Infectious and Human Genetic Materials quarantine), unmanipulated patient blood cells and customized cellular therapies cannot be exported cross-border as commercial merchandise.
- The Compliant Destination Route: International patients must travel to Shanghai to receive complete on-ground care: clinical eligibility evaluation, apheresis, bridging therapy, GMP cell manufacturing, pre-infusion conditioning, inpatient infusion, and post-infusion immune surveillance.
- Substantial Health-Economic Advantage: Receiving commercial CAR-T therapy at top Shanghai teaching hospitals offers total treatment package costs (including cell manufacturing, specialized hospital admission, and intensive monitoring) at approximately 30%–40% of the cost charged by Western medical centers in the US or Europe, creating life-saving accessibility for international patients.
4. How CMCS Navigates International Patient Referrals & Clinical Collaborations
For overseas cancer centers, private medical groups, and international patients, CMCS provides structured, medically governed concierge and coordination pathways:
- Preliminary Eligibility & Prior Therapy Screening: We review recent medical documentation (pathology, immunohistochemistry for CD19 expression, PET-CT staging, and prior systemic chemotherapy/transplant records) to answer 3–5 initial procedural and medical feasibility questions.
- Formal Multidisciplinary Review (USD 100 Initiation Fee): Upon receipt of formal medical records and patient authorization, CMCS engages senior hematology professors at Ruijin or Renji Hospital to provide an independent clinical assessment regarding eligibility, apheresis feasibility, and anticipated treatment timeline. (The USD 100 initiation fee is fully creditable toward subsequent on-ground follow-up services).
-
End-to-End On-Ground Care Coordination in Shanghai:
- Fast-track medical visa documentation and hospital international admission booking.
- Coordination of leukapheresis scheduling and direct logistics integration with Fosun Kite's Zhangjiang manufacturing plant.
- Dedicated bilingual medical translation during hospital consultations and inpatient stays (Routine coordination at USD 259/person/day; complex/critical care at USD 389/person/day).
- Post-discharge follow-up scheduling, immunoglobulin G (IgG) maintenance monitoring, and coordinated transfer back to the patient’s home oncologist.
- Institutional Collaboration Agreements: CMCS facilitates formal clinical referral pathways and academic observational exchanges between overseas private hospital groups and Shanghai hematology centers.
Regulatory & Compliance Notice
China Medical Concierge – Shanghai (CMCS) is an independent healthcare management and medical concierge service provider based in Shanghai. CMCS is NOT a hospital, cellular laboratory, or drug distributor. CMCS does NOT sell, distribute, or export cellular therapies or human biological specimens. Axicabtagene Ciloleucel is an autologous individualized cell therapy that must be administered within qualified, certified clinical medical centers in Shanghai. All clinical assessments, patient selection, conditioning chemotherapy, cell infusions, and adverse reaction management are determined and executed independently by licensed hematology specialists at accredited Shanghai tertiary hospitals.
Initiate a Case Evaluation or Clinical Referral
To submit medical records for an independent CAR-T feasibility review at a top Shanghai academic hematology center, or to discuss institutional referral collaboration, please contact our international liaison office:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
0 Kommentare